Johnson & Johnson (JNJ)vsP3 Health Partners Inc (PIII)
JNJ
Johnson & Johnson
$270.70
+0.56%
HEALTHCARE · Cap: $648.67B
PIII
P3 Health Partners Inc
$7.05
-0.56%
HEALTHCARE · Cap: $1.61B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 6416% more annual revenue ($97.93B vs $1.50B). JNJ leads profitability with a 21.5% profit margin vs -6.5%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
PIII
Hold38
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : PIII
PIII has a balanced fundamental profile.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : PIII
The primary concerns for PIII are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.80 is elevated, increasing financial risk.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PIII is a turnaround play — different risk/reward profiles.
PIII carries more volatility with a beta of 1.62 — expect wider price swings.
PIII is growing revenue faster at 8.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 38/100), backed by strong 21.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →P3 Health Partners Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
P3 Health Partners Inc (PIII) is a forward-thinking healthcare organization dedicated to enhancing care quality and minimizing costs through innovative, data-driven methodologies. Specializing in value-based care models, the company leverages telehealth technologies and advanced analytics to deliver tailored healthcare solutions, particularly targeting underserved populations. By collaborating with community organizations and maintaining a robust network of primary care providers and specialists, PIII addresses the growing demand for efficient healthcare services. With a steadfast commitment to high-quality, cost-effective care, PIII is well-positioned to thrive in the evolving healthcare environment.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?